Take Stock Foods key facts
as of Oct 2026- Producer of food products intended to provide broth packed with essential mood and health-boosting nutrition.
- Take Stock Foods is valued at approximately $17.3M as of Oct 2026 (last reported valuation).
- It has raised $4.0M; the latest was Accelerator/Incubator in Mar 2025.
- Notable investors include SyndicateRoom, Active Partners, Tesco Accelerator Programme, Alistair Brownlee, Giles Brook — 11 tracked in total.
- Status: Privately Held (backing).
Take Stock Foods's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·The complete investor list: 11 names
- ·Watch Take Stock Foods: the Monday email on marks, rounds and moves
Take Stock Foods funding rounds
No funding rounds for Take Stock Foods are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Take Stock Foods
11+Membership and data by Private Market View
Take Stock Foods valuation
Take Stock Foods's last reported valuation was $17.3 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
Take Stock Foods investors
11 investors are on record for Take Stock Foods, including SyndicateRoom, Active Partners, Tesco Accelerator Programme and Alistair Brownlee.
About Take Stock Foods
Producer of food products intended to provide broth packed with essential mood and health-boosting nutrition. The company simmers meaty bones, veg, and herbs to make natural bone broths o support health with natural ingredients, packed with collagen, protein, and amino acids, enabling customers to benefit from nutritious, wholesome food in convenient, recyclable packaging and to enhance well-being with a convenient, flavorful, and nutritious superfood.
- Sector
- Consumer Products and Services (B2C)
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 32
- Website
- frejabonebroth.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.